Study objective: We compare metoclopramide 20 mg intravenously, combined with diphenhydramine 25 mg intravenously, with ketorolac 30 mg intravenously in adults with tension-type headache and all nonmigraine, noncluster recurrent headaches.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs are commonly used to treat tension-type headache. 1 Several studies have also demonstrated efficacy of parenteral dopaminergic antagonists such as chlorpromazine 2 and metoclopramide 3 for these headaches. Comparative efficacy studies of the dopamine antagonists versus the nonsteroidals have yet to be performed. One aim of this study was to compare the efficacy in tensiontype headache of intravenous metoclopramide, a safe and welltolerated dopamine receptor antagonist, with that of intravenous ketorolac, a parenteral nonsteroidal antiinflammatory drug.
Patients who present to an emergency department (ED) for treatment of an acute exacerbation of a recurrent headache disorder at times cannot receive a formal headache diagnosis because of bland or conflicting headache features, prolonged headache duration, or a history of only infrequent recurrence of headache. 4 These difficult-to-classify headaches will either continue to recur and ultimately meet criteria for one of the named headache disorders, such as tension-type, migraine, or cluster, or resolve and thus not require classification. In clinical practice, when these headaches present to our ED acutely, we treat them as presumptive tension-type headache with nonsteroidal anti-inflammatory drugs or as presumptive migraine, with dopamine antagonists.
In this study, we lumped nonmigraine, noncluster recurrent headaches together with tension-type headache because this reflects a clinical reality: once clinicians exclude a pathologic underlying cause of headache from the differential diagnosis, and when the headache lacks the requisite features to support the diagnosis of migraine or cluster, subtleties in headache nosology are of only marginal practical use to emergency clinicians. This approach has ample precedent in emergency medicine headache research, in which researchers often aggregate all benign headaches. [5] [6] [7] It may also reflect a reality of headache nociception known as the "convergence hypothesis," which posits that various distinct primary headaches are manifestations of the same underlying neuropathophysiology. 8 In this study we tested 2 distinct hypotheses:
• Hypothesis 1: In a population of patients with an exacerbation of a recurrent headache meeting neither migraine nor cluster headache criteria, 20 mg of intravenous metoclopramide combined with 25 mg of intravenous diphenhydramine will produce greater relief of headache 60 minutes after medication administration than will 30 mg of intravenous ketorolac.
• Hypothesis 2: Within the subset of patients meeting International Headache Society criteria for tension-type headache, 20 mg of intravenous metoclopramide combined with 25 mg of intravenous diphenhydramine will also produce greater relief of headache 60 minutes after medication administration than will 30 mg of intravenous ketorolac.
MATERIALS AND METHODS

Study Design and Setting
This was a randomized, double-blind trial comparing 2 parenteral treatments among patients presenting to our ED with nonmigraine, noncluster recurrent headache and tension-type headache. The Montefiore Medical Center institutional review board approved this protocol. We registered it at http://clinicaltrials.gov (NCT01011673).
This study was performed in the ED of Montefiore Medical Center, an urban teaching hospital with more than 100,000 adult visits annually. Salaried, trained, fluently bilingual (English and Spanish) research associates staff the ED 24 hours per day, 7 days per week.
Selection of Participants
Research associates screened adult patients younger than 65 years who presented to our ED with headache. Those who had a recurrent episode of a headache experienced at least once before were eligible for participation, provided they did not meet migraine or cluster headache criteria as defined by the International Headache Society's International Classification of Headache Disorders, 2nd Edition. 9 We excluded patients if the attending physician was suspicious of a serious secondary cause of headache, for temperature greater than 100.4°F (38°C), a new objective neurologic abnormality, allergy, active gastritis or peptic ulcer disease, history of upper gastrointestinal bleeding, organ transplant, use of a monoamine oxidase inhibitor, pregnancy, lactation, or previous enrollment. We asked patients a series of close-ended questions about their current headache and their headache history, which allowed us to define the subgroup who met criteria for tension-type headache (International Classification of Headache Disorders 2.1, 2.2, or 2.3) 9 ( Figure 1 ).
Interventions
The research pharmacist performed randomization in blocks of 6, using an online random-number generator. The pharmacist filled medication vials and placed them into sequentially numbered research bags. Research associates then allocated the bags to patients in order. Only the pharmacist, whose records were maintained in a location distant from the ED and unavailable to the investigators, knew the assignment. Every research bag in the metoclopramide/diphenhydramine arm held 2 vials, one containing 20 mg of metoclopramide and one containing 25 mg of diphenhydramine. Every bag in the ketorolac arm also held 2 vials, one containing ketorolac 30 mg and one containing normal saline solution placebo. The contents of these vials were clear and indistinguishable. Normal saline solution was added to the ketorolac vial to make the volume in each vial identical. To maintain allocation
Editor's Capsule Summary
What is already known on this topic
The best nonopioid therapy for headaches remains unclear.
What question this study addressed
Which is better for nonmigraine, noncluster recurrent headaches: metoclopramide 20 mg plus diphenhydramine 25 mg intravenously or ketorolac 30 mg intravenously?
What this study adds to our knowledge All measures of pain relief were superior in the metoclopramide plus diphenhydramine group in this randomized, blinded, controlled trial of 120 adults.
How this is relevant to clinical practice
In the doses used in this study, metoclopramide plus diphenhydramine was better than ketorolac for nonmigraine, noncluster recurrent headaches.
A.
At least 10 episodes fulfilling criteria B-E B.
Headache lasting 30 minutes to 7 days C.
Headache has at least two of the following characteristics 1. Bilateral location 2.
Pressing/ tightening (non-pulsating) quality 3.
Mild or moderate intensity (may inhibit but not prohibit usual activities) 4.
Not aggravated by routine physical activity such as walking or climbing stairs D.
Both of the following 1.
No nausea or vomiting (anorexia may occur) 2.
No more than one of photophobia or phonophobia E.
Not attributed to another disorder Figure 1 . concealment, a nurse, also blinded, placed the 2 vials from each bag in a 50-mL bag of normal saline solution for administration to the patient as an intravenous drip during 15 minutes (200 mL/hour). We chose to use 20 mg of metoclopramide rather than a more standard 10-mg dose to avoid failure to detect a benefit of the drug because of underdosing. Because akathisia is common among patients who receive higher doses of intravenous metoclopramide, we coadministered diphenhydramine to all patients who received it.
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Methods of Measurement
After obtaining informed written consent, research associates performed a brief pain assessment, using a structured questionnaire (Appendix E1, available online at http://www.annemergmed.com). The nurse then administered the intravenous solution. The research associates returned every 30 minutes to ascertain the patient's pain level. At 1 and 2 hours after medication administration, the research associates asked a more detailed series of questions. Patients who required additional analgesia after 1 hour had elapsed were administered medication at the discretion of the treating physician. We contacted patients by telephone 24 hours after ED discharge to ascertain headache status, satisfaction with treatment, and occurrence of adverse events.
Outcome Measures
As a primary endpoint, we used an 11-point numeric rating scale 11 that asked patients to assign their pain a number between zero and 10, with zero representing no pain and 10 representing the worst pain imaginable. The primary outcome was the between-group difference in the 1-hour change in this scale. Secondary outcome measures included (1) response to the question, Do you want to receive the same medication the next time you come to the ED with a headache?; (2) headache freedom achieved in the ED without the use of rescue medication; (3) receipt of rescue medication at any time during the ED visit, defined as any medication administered specifically to alleviate headache; (4) sustained headache freedom, defined as achieving headache freedom in the ED and maintaining it for 24 hours without rescue medication; (5) use of rescue medication during the 24 hours after initial medication administration; and (6) percentage improvement in pain score between baseline and 1 hour, defined as (baseline pain score-1-hour pain score)/baseline pain score.
One hour after medication administration, we asked patients whether they felt drowsy and had them choose one of the following 3 options: no drowsiness, a little bit drowsy but able to function, or too drowsy to function. At the follow-up telephone call, we asked patients whether they felt restless at any time after receiving the intravenous medication in the ED and had them choose one of the following 3 options: no restlessness, a little bit restless, or very restless. We also asked them at 1 and 2 hours and at the 24-hour follow-up interview whether they 16 (27) 11 (18) Median baseline NRS pain score, on a scale from 0-10 with 0ϭno pain and 10ϭworst imaginable (IQR) 8 (7, 10) 8 (7, 9) IQR, interquartile range; NRS, numerical rating scale; h, hours; mo, months; n, number.
experienced any other symptoms. If they answered in the affirmative, their symptoms were elicited with an open-ended question.
Research associates collected data with paper data collection forms. The principal investigator, who remained blinded to allocation assignment during this process, then transcribed the data into SPSS (version 19; SPSS, Inc., Chicago, IL).
Primary Data Analysis
According to previous work, 12,13 our sample size calculation assumed normal distribution and a conservative ␣ and was driven by the need to identify statistically significant betweengroup differences in the subgroup of patients with tension-type headache. We estimated that a sample size of 44 patients in each arm would give us a power of 0.8 to detect a between-group difference in improvement in pain score of 2.0 units, a difference considered clinically robust. 14 We estimated that enrolling 88 patients with tension-type headache would require enrolling 50% more patients, ie, about 130 patients with bland headache, but planned to stop as soon as we had obtained complete data on the subset of 88 patients with tension-type headache.
When analyzed, the continuous outcome data did not distribute normally, so we presented these data as medians with interquartile range and used the Hodges-Lehman estimate to construct 95% confidence interval (CI) for difference between medians. We expressed between-group differences in dichotomous outcomes as proportions bounded by 95% CIs and report for these the number needed to treat, that is, the number of patients who would need to be treated with the more efficacious medication rather than the less efficacious one for a single patient to achieve the target outcome of interest.
We analyzed data with a per-protocol analysis. This seemed to us more clinically sensible than an intention-to-treat strategy because, on review of the data set before unblinding, 3 randomized patients clearly were enrolled in error according to their ultimate diagnoses: subarachnoid hemorrhage, brain abscess, and malaria. Thus, as shown in the Consolidated Standards of Reporting Trials (CONSORT) diagram ( Figure  1) , we excluded these patients from further analysis.
RESULTS
Enrollment for this study began in November 2009 and continued for 35 months. During this time, we approached 783 patients for participation and included 120 in the analysis (Figure 2) . Of the 120 patients enrolled with bland headache, 89 of these met criteria for tension-type headache.
Baseline characteristics were comparable between the 2 groups (Table 1) .
Patients with nonmigraine, noncluster recurrent headache who received the metoclopramide combination had greater pain relief than those randomized to ketorolac, as measured by change in pain scores (Table 2, Figure 3 , Appendix E2 available online at http://www.annemergmed.com). The patients who received the metoclopramide combination were also more likely to achieve headache freedom in the ED, experience sustained headache freedom throughout the 24 hours after medication administration, and reported wanting the same medication if treated again in the ED for similar headache (Table 3 ). These patients were less likely to require rescue medications (Table 3) . At 1 hour, patients who received the metoclopramide combination improved by a median of 71% (IQR 35%, 100%), whereas those who received ketorolac improved by a median of 44% (IQR 23%, 83%) ( Figure 4 ). These findings were nearly identical to the outcome data for the subset of patients with tension-type headache (Tables 2 and 4 ). There were no serious or unexpected adverse events. The development of new symptoms after investigational medication administration was reported by 14 of 60 (23%) patients in the ketorolac arm and 12 of 60 (20%) patients in the metoclopramide arm (95% CI for difference of 3% Ϫ11% to 18%). These mostly consisted of evolving headache descriptions such as pulsating pain, severe headache, and facial pressure. Drowsiness at 1 hour was more common among patients who received the metoclopramide combination, although drowsiness sufficient to impair function was uncommon in both groups (Table 5 ). Restlessness after receiving the investigational medications was evenly distributed between the 2 groups (Table  5 ). In general, the medications were very well tolerated. Of the 16 patients who reported they would not want to receive the same medication at the next visit, all cited lack of efficacy rather than adverse effects as their rationale. Other infrequent adverse events are listed in Table 5 .
LIMITATIONS
We sought to exclude patients with migraine from this study according to strict application of International Headache Society criteria to the patient's self-described headache characteristics at enrollment. However, during their time in the ED, some patients developed nausea or had their headache evolve into a typical migraine headache. This is a relatively common phenomenon that has been reported previously. 15 The effect of this may have been to dilute our "homogenous" population of tension-type headache, potentially causing misclassification bias, which tends to drive outcomes toward the null.
A second limitation, which is common to most single-site studies, is that, despite the internal validity of our findings, we conducted this research in 1 urban ED in the Bronx, NY, caring for a largely nonwhite underserved population. This necessarily limits any claims of external validity or generalizability.
Finally, it took us nearly 3 years to enroll enough patients to meet our sample size requirements. We believe this reflects the clinical reality that the majority of recurrent headache disorders treated in emergency practice are migraine or probable migraine. Despite the prevalence of tension-type headache in the population, acute episodes of severe or functionally disabling tension-type headache are relatively uncommon in the ED.
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DISCUSSION
The preponderance of data from this study suggests that the intravenous combination of metoclopramide 20 mgϩdiphenhydramine 25 mg is more efficacious than 30 mg of intravenous ketorolac for treatment of acute nonmigraine, noncluster recurrent headaches and for tension-type headache. Patients who received metoclopramide were significantly more likely than patients who received ketorolac to achieve headache relief in the ED, experience sustained headache freedom during the 24 hours after medication administration, and report wanting the same medication if treated again in the ED for similar headache. They were also 3 times less likely to require rescue medication than patients who received ketorolac. Both treatments used in this study were well tolerated. Restlessness, a common akathetic adverse effect of metoclopramide, seems to have been prevented successfully by the coadministration of diphenhydramine. The metoclopramide combination caused mild drowsiness in two thirds of the patients who received it compared with about one third of patients who received ketorolac. However, of the patients who reported some level of drowsiness, very few reported being "too drowsy to function." A lower dose of metoclopramide may lessen the rate of drowsiness, although this may also lessen the efficacy. The choice of any treatment reflects a tradeoff between efficacy and adverse effects. In this case, the consistency and the magnitude of the findings supporting the metoclopramide combination over ketorolac coupled with the patients' frequently stated desire to receive this medication again, suggest that the benefits of the metoclopramideϩdiphenhydramine outweigh the harm.
Others have demonstrated that intravenous chlorpromazine, another dopamine antagonist, and intravenous metoclopramide are more effective than placebo for tension-type headache. Bigal et al 2 tested chlorpromazine, dosed at 0.1 mg/kg, versus placebo in a randomized double-blind study conducted in public health clinics in Brazil. These authors reported a number needed to treat of 2 versus placebo for achieving a pain-free state by 60 minutes. Cicek et al 3 randomized 140 patients with acute tension-type headache to receive metoclopramide 10 mg intravenous alone, metoclopramide 10 mg intravenousϩpethidine (meperidine) 50 mg intramuscularly, pethidine 50 mg intramuscularly alone, or placebo. With regard to need for rescue medication, the authors reported a number needed to treat of 2 for metoclopramide versus placebo and a number needed to treat of 3.5 for metoclopramide versus pethidine. The fact that both migraine and tension-type headaches appear to respond well to metoclopramide, a medication without inherent analgesic properties, raises intriguing questions about headache nosology. 16 It may be that tension-type headache and migraine are unique disease processes with a common final nociceptive pathway where metoclopramide may act. Alternatively, it may be that these 2 headache types share a similar pathophysiology, which presents with multiple phenotypes. To the best of our knowledge, there are no pharmacodynamic or mechanistic data that explain metoclopramide's efficacy in acute headache.
During this study, once migraine and cluster headache had been excluded, we did not seek to classify any additional headache disorders other than tension-type headache. We assumed homogeneity of response among the various uncommon headaches that do not meet migraine, cluster, or tension-type criteria, such as nummular headache, 17 noninfectious rhinosinusitis-like headache, 18 and hemicrania continua, 15 an assumption that may not be strictly correct. Hemicrania continua, for example, is defined by its response to indomethacin 15 and thus may be more likely to respond to ketorolac. However, the subset of patients with tension-type headache responded identically to each medication compared with the study population as a whole. This leads us to conclude that these less common headache types either were underrepresented in our study population or responded to the investigational medications in a manner comparable to tensiontype headache.
In conclusion, for adults presenting to an ED with tensiontype headache or with nonmigraine, noncluster recurrent headache, intravenous metoclopramideϩdiphenhydramine provided more headache relief than intravenous ketorolac. Author contributions: BWF, CS, DE, PEB, and EJG conceived and designed the study. BWF, VA, and CC reviewed data for integrity and to confirm diagnosis. BWF and DE supervised the conduct of the trial and data collection. BWF analyzed the data and drafted the article, and all authors contributed substantially to its revision. BWF takes responsibility for the paper as a whole. APPENDIX E2. Histograms of pain scores at baseline, one hour, and baseline-one hour for each medication arm.
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